AstraZeneca says its coronavirus vaccine can stop severe disease despite 'limited' success against South African variant
Posted 5h ago
[...]
British company AstraZeneca says it believes its COVID-19 vaccine developed with Oxford University can protect against severe disease caused by the South African variant of the virus.
Key points:
* Around 2,000 people took part in the trial
* None of the participants were hospitalised or died after receiving the vaccine
* But it showed "limited efficacy" against mild disease due to the South African variant
But AstraZeneca confirmed that early data from a small trial had shown only limited efficacy for the vaccine against mild disease primarily due to this variant.
"Why Oxford’s positive COVID vaccine results are puzzling scientists [...] But the analysis found a striking difference in efficacy, depending on the amount of vaccine delivered to a participant. A regimen consisting of two full doses given a month apart looked to be just 62% effective. But, surprisingly, participants who received a lower amount of the vaccine in a first dose and then the full amount in the second dose were 90% less likely to develop COVID, compared with participants in the placebo arm."
It was Plato who said, “He, O men, is the wisest, who like Socrates, knows that his wisdom is in truth worth nothing”